NIH VideoCast - The AML genome(s): Mutations in four dimensions

Skip Navigation

The AML genome(s): Mutations in four dimensions

Loading... Loading video...

443 Views

Air date:	Wednesday, September 30, 2015, 3:00:00 PM Time displayed is Eastern Time, Washington DC Local
Views:	Total views: 443 (136 Live, 307 On-demand)
Category:	WALS - Wednesday Afternoon Lectures
Runtime:	01:10:11
Closed captioning:	Check box to display CC outside of the video Note: You can drag the captioning window around and resize it
Description:	NIH Director’s Wednesday Afternoon Lecture Series For many years, Dr. Ley's laboratory has used mouse models of acute myeloid leukemia (AML) to establish key principles of AML pathogenesis. The lab established that the initiating event for Acute Promyelocytic Leukemia is the PML-RARA fusion gene created by the t(15;17) that is found in nearly all patients with this disease. The roles of cooperating mutations and the cellular milieu for APL pathogenesis have also been established. In collaboration with the Genome Institute at Washington University, the investigators of the Genomics of AML PPG (TJ Ley, PI) sequenced the first human cancer genome (a patient with AML) and the first mouse cancer genome (from the mouse model of APL), and have discovered several new recurrent mutations that are important for AML pathogenesis and outcomes, including recurring mutations in DNMT3A and IDH1/2, among many others. These data are now being correlated to RNA expression, DNA methylation, protein abundance and modification, and clinical datasets. These efforts will hopefully lead to new tests to better establish prognosis, and new approaches for the therapy of patients with this disease. For more information go to https://oir.nih.gov/wals

NLM Title:	The AML genome(s) : mutations in four dimensions / Timothy J. Ley.
Author:	Ley, Timothy J. National Institutes of Health (U.S.),
Publisher:
Abstract:	(CIT): NIH Director"s Wednesday Afternoon Lecture Series For many years, Dr. Ley's laboratory has used mouse models of acute myeloid leukemia (AML) to establish key principles of AML pathogenesis. The lab established that the initiating event for Acute Promyelocytic Leukemia is the PML-RARA fusion gene created by the t(15;17) that is found in nearly all patients with this disease. The roles of cooperating mutations and the cellular milieu for APL pathogenesis have also been established. In collaboration with the Genome Institute at Washington University, the investigators of the Genomics of AML PPG (TJ Ley, PI) sequenced the first human cancer genome (a patient with AML) and the first mouse cancer genome (from the mouse model of APL), and have discovered several new recurrent mutations that are important for AML pathogenesis and outcomes, including recurring mutations in DNMT3A and IDH1/2, among many others. These data are now being correlated to RNA expression, DNA methylation, protein abundance and modification, and clinical datasets. These efforts will hopefully lead to new tests to better establish prognosis, and new approaches for the therapy of patients with this disease.For more information go to https://oir.nih.gov/wals.
Subjects:	Leukemia, Myeloid, Acute--genetics
Publication Types:	Lecture Webcast

NLM Classification:	QZ 350
NLM ID:	101671873
CIT Live ID:	16906
Permanent link:	https://videocast.nih.gov/watch=16906

Related Videos...